In a letter sent to the head of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, Wolfe outlined a statistical analysis he had done of a 1999 Pfizer-funded test of Celebrex as a preventative for Alzheimer's disease that had just been made available on an industry Web site of clinical trial results.

FORBES: The Celebrex Safety Mirage